Tilray | TRLY - Ebitda

Stock Price
9.44
Daily Change
-0.04 -0.42%
Monthly
-7.99%
Yearly
926.09%
Q1 Forecast
9.24

Tilray reported $8.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acasti Pharma USD -3.18M 521K Mar/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Avita Medical AUD -9.69M 12.21M Dec/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Cronos Group USD 456K 5.22M Dec/2025
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
IQVIA Holdings USD 1.05B 97M Dec/2025
Knight Therapeutics CAD 20.99M 5.48M Sep/2025
Moderna USD -790M 582M Dec/2025
Organigram Holdings CAD 6.15M 455K Sep/2025
Organon & Co USD 383M 135M Dec/2025
Revvity USD 248.91M 48.52M Dec/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1B 151.5M Dec/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025